Genomics Translation Projects Supported by AHRQ
ShareCompartir
This website is archived for historical purposes and is no longer being maintained or updated.
Evidence evaluation for clinical guidelines/recommendations
Evidence evaluation for other stakeholders
Creating new evidence
Knowledge dissemination
Methods and conceptual frameworks
Evidence evaluation for clinical guidelines/recommendations:
- BRCA mutation testing – U.S. Preventive Services Task Force (Completed September 2005)
- Screening for hemochromatosis – U.S. Preventive Services Task Force (Completed August 2006)
- CYP450 testing in depression – Evaluation of Genomic Applications in Practice and Prevention (Completed January 2007)
- Gene expression profiling (GEP) tests in breast cancer – Evaluation of Genomic Applications in Practice and Prevention (Completed January 2008)
- HNPCC testing in colorectal cancer – Evaluation of Genomic Applications in Practice and Prevention (Completed May 2007)
- Factor V/Prothrombin mutation testing – Evaluation of Genomic Applications in Practice and Prevention (Completed June 2009)
Evidence evaluation for other stakeholders:
- Assessment of Thiopurine Methyltransferase Activity in Patients Prescribed Azathioprine or Other Thiopurine-based Drugs
- Genomic testing in ovarian cancer – CDC (Completed October 2006)
- Horizon scan on use of genetic testing in cancer – CMS (Completed January 2006)
- Horizon scan on genetic tests in non-cancer diseases – CMS[PDF – 171 KB] (Completed August 2007)
- Selected pharmacogenetic tests for non-cancer and cancer conditions – CMS [PDF – 2.3 MB] (Completed November 2008)
- BNP testing in heart failure – AACC, ACP, ACEP, ACCP (Completed September 2006)
- HER2/Neu testing in breast and other solid tumors – AACC (Completed November 2008)
- Cancer family history – CDC
- Cancer family history: collection and use (Completed October 2007)
- Cancer family history: clinical utility (Completed April 2009)
- Family history in primary care – NIH (state of science conference) (Completed September 2009)
Creating new evidence:
- Infrastructure for monitoring utilization and outcomes of gene-based clinical applications: an assessment – CDC (Completed May 2008)
- Cost-effectiveness of DNA stool testing in colorectal cancer – CMS[PDF – 729 KB] (Completed December 2007)
- Comparison of gene-based to non-gene-based dosing on outcomes of warfarin therapy
- Role of OCT genetic variations in metformin effectiveness – NIH co-funding
- Pharmacogenetic evaluation of QTc prolongation in women entering a methadone maintenance treatment program
- Clinical and economic implications of genetic testing for warfarin management
Knowledge dissemination:
Methods and conceptual frameworks:
- Analytic validity, quality rating and evaluation frameworks for genetic and other laboratory tests
- Genetic testing – draft chapter in methods guide for comparative effectiveness reviews (Completed August 2009)
- DARTNet (distributed ambulatory research in therapeutics network): a new electronic infrastructure for conducting comparative effectiveness studies in EMR-enabled clinics in primary practice (Completed May 2008)
- HMORN distributed research project (Completed 2009)
- Page last reviewed: December 28, 2010 (archived document)
- Content source: